Sponsor or institution
Clinical trials and research at Cancer Institute and Hospital, Chinese Academy of Medical Sciences
As of November 12, 2026, Find a Trial lists 149 clinical trials run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences that are recruiting, in China. 4 were first registered in the last 30 days. By phase: Phase 2 (64), Phase 3 (12), Phase 1 (10), Early Phase 1 (9). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 149Clinical trials
- 4New in 30 days
- 1Country
Newest trials
All recruiting trials (149)
-
Cadonilimab and Lenvatinib in advanced kidney cancer
This study tests whether Cadonilimab plus Lenvatinib can help adults with unresectable, advanced renal cell carcinoma, especially clear cell type, after prior treatments.
-
Neoadjuvant therapy with nimotuzumab, toripalimab, nab-paclitaxel, and cisplatin for locally advanced head and neck cancer
This study tests a pre-surgery treatment combining targeted therapy, immunotherapy, and chemotherapy to see if it helps patients with locally advanced, resectable head and neck squamous cell carcinoma.
-
Toripalimab Plus Cetuximab and Irinotecan for second-line right-sided colon cancer
This phase II study tests whether a combo of toripalimab, cetuximab, and irinotecan helps adults with second-line, right‑sided, RAS/BRAF wild-type advanced colon cancer.
-
Primary tumor removal with targeted lymph node removal plus radiation for biliary tract cancer with lymph node spread
This phase II study tests whether removing the main tumor and select nearby lymph nodes, followed by postoperative radiation, helps patients with biliary tract cancer and lymph node metastases.
-
Three-dimensional lattice radiotherapy with PD-1/PD-L1 inhibitors for advanced solid tumors
This study tests whether adding lattice radiotherapy to PD-1/PD-L1 inhibitors is safe and helps people with advanced solid tumors that have grown or spread.
-
Radiotherapy target-volume choices in locally advanced esophageal cancer during immunotherapy
This observational study looks at how doctors outline the radiation area for locally advanced esophageal squamous cell cancer patients treated with radiotherapy and immunotherapy to see which approaches correlate with better outcomes.
-
Rimegepant plus toripalimab in advanced urothelial cancer after standard therapy
This small, early-stage study tests whether combining rimegepant with toripalimab is safe and shows signs of activity in adults with advanced urothelial cancer that did not respond to prior treatment.
-
YSCH-01 Nebulized Therapy for Lung Metastases in NSCLC and Advanced Solid Tumors
A first-in-human, early-phase study tests a nebulized therapy called YSCH-01 to see if it is safe and shows any signs of benefit for adults with NSCLC or other cancers that have spread to the lungs.
-
Multi-omics model to predict treatment response in early triple-negative breast cancer
A multimodal approach tests whether combining clinical data, imaging, pathology, and molecular data can predict which early TNBC patients will respond to treatment.
-
MRI-based AI to classify and grade renal tumors
This study tests AI methods on MRI data from adults with kidney tumors to see if they can identify tumor type and grade before surgery.
-
Fruquintinib plus anti-EGFR antibody for third-line metastatic colorectal cancer
This study tests whether adding fruquintinib to cetuximab-beta helps adults with RAS wild-type metastatic colorectal cancer who have already tried and not benefited from at least two prior treatments.
-
Sintilimab plus IMRT and capecitabine as an alternative to mitomycin in limited-stage anal squamous cell carcinoma
This trial tests whether replacing mitomycin with the PD-1 inhibitor sintilimab during chemoradiotherapy is at least as effective in achieving complete response after treatment for limited-stage anal squamous cell carcinoma.
-
Chemoradiotherapy with CAPOX and SHR-1701 for unresectable gastric or GEJ cancer
This study tests whether adding SHR-1701 to radiotherapy and CAPOX helps patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction cancer see if they harm or help, with the goal of delaying progression and enabling possible surgery.
-
Moderately hypofractionated radiotherapy after hysterectomy for cervical cancer
This study tests whether a shorter, moderately intensified radiotherapy course after surgery is safe and effective for patients with cervical cancer.
-
Long-term survival and AI-based prediction in NSCLC patients treated with immunotherapy
This study tests whether AI analysis of routine pathology images, along with multi-omics data, can predict long-term survival for people with advanced NSCLC treated with immunotherapy.
-
Predictive value of tumor microenvironment PET/CT for aggressive lymphoma
This study tests whether imaging of the tumor microenvironment can predict how patients with aggressive lymphoma will respond to treatment and what their prognosis might be.
-
Connectome-guided navigation for eloquent-area brain tumor surgery
We’re testing whether using a patient’s brain network maps to guide tumor removal in eloquent areas helps preserve function better than standard tractography-guided surgery.
-
Gutong Plaster at Acupoints for Moderate to Severe Cancer Pain
This study tests whether applying Gutong Plaster at acupuncture points, in addition to standard opioid therapy, can better reduce pain and lower opioid use for adults with moderate to severe cancer pain.
-
VSV-based viruses for advanced solid tumors using multiple delivery routes
This trial tests whether giving vesicular stomatitis virus (VSV) injections carrying different targets is safe and tolerable in adults with advanced solid tumors who have limited treatment options.
-
Postoperative chemoradiotherapy for extrahepatic cholangiocarcinoma and gallbladder cancer
This study tests whether giving concurrent chemotherapy with radiotherapy after curative surgery helps patients with high-risk extrahepatic bile duct cancer or gallbladder cancer.
-
RAIRI-guided risk-stratified adjuvant therapy after chemoradiotherapy in nasopharyngeal carcinoma
This real-world study tests whether the RAIRI model can predict who will benefit from adjuvant therapy after chemoradiotherapy for non-metastatic nasopharyngeal carcinoma.
-
RAIRI-guided adjuvant therapy in nasopharyngeal carcinoma
This trial tests whether using the RAIRI risk model to guide adjuvant therapy after chemoradiotherapy can spare some patients unnecessary treatment in locoregionally advanced nasopharyngeal carcinoma.
-
Combination therapy with BRII-5395, sintilimab, and bevacizumab in advanced HBV-related hepatocellular carcinoma
This early-phase study tests BRII-5395 together with two approved cancer drugs to see if it is safe and tolerable in people with advanced HBV-related liver cancer.
-
CREPT urine test to diagnose and monitor bladder cancer
This project will test whether measuring CREPT levels in exfoliated urothelial cells from urine can help diagnose bladder cancer and detect recurrence in adults.
-
Long-term outcomes after first-line tislelizumab plus chemotherapy in advanced squamous NSCLC
This project collects long-term survival data from people with advanced squamous non-small cell lung cancer who received first-line tislelizumab plus chemotherapy in RATIONALE-307 to see who benefited most.
-
Combining anlotinib with whole-brain radiotherapy for SCLC brain metastases
This trial will test whether adding the targeted drug anlotinib to whole-brain radiotherapy helps people with small cell lung cancer who have brain metastases.
-
177Lu-CTR-FAPI for thyroid cancer
This will try a radioactive drug called 177Lu-CTR-FAPI in people with progressive, radioactive iodine–refractory thyroid cancer to see if it is safe and helps shrink tumors.
-
Intraperitoneal SK-NK cell infusion for advanced ovarian cancer with massive ascites
This will try giving highly activated donor NK cells directly into the abdomen once weekly for four weeks to see if it helps people with advanced ovarian cancer who have large-volume malignant ascites and no standard treatment options.
-
Aitua plus Nab-Paclitaxel and Carboplatin before surgery for advanced high-grade serous ovarian cancer
This trial tests whether adding the PD-1/CTLA-4 bispecific antibody Aitua to standard neoadjuvant chemotherapy helps achieve complete tumor removal before interval debulking surgery in newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer patients who are not expected to be debulked to no visib
-
In vivo CAR‑T treatment targeting BCMA, GPRC5D, DLL3, and FcRH5 for advanced tumors
This trial will try an in-body CAR-T injection to treat adults with relapsed or refractory advanced blood cancers or solid tumors that express BCMA, GPRC5D, DLL3, or FcRH5.
-
Precision surgery guided by 68Ga-CTR-FAPI for newly diagnosed medullary thyroid cancer
This trial will test whether using 68Ga-CTR-FAPI PET-CT to guide the extent of surgery improves biochemical cure rates for people with newly diagnosed medullary thyroid carcinoma.
-
Predicting and preventing surgical wound infections after brain or spinal tumor surgery
This trial will test whether a machine-learning tool that flags people having brain or spine tumor surgery for extra infection-prevention care can lower their risk of surgical wound infections.
-
Personalized local treatment for breast cancer with involved supraclavicular or internal mammary lymph nodes
This trial tests a personalized plan of shorter-course radiotherapy with a targeted boost, surgery when needed, and tailored extra systemic therapy to see if it improves progression-free survival for adults whose breast cancer involves nearby supraclavicular or internal mammary lymph nodes.
-
Safety and tolerability of NEUK203-13 CAR-NK cells for DLL3 in advanced neuroendocrine tumors
This early phase trial tests NEUK203-13, an off-the-shelf CAR-NK cell therapy, in adults with advanced SCLC or other neuroendocrine tumors to see if it is safe and if it shows any anti-tumor activity.
-
CREPT-618 for adults with locally advanced liver cancer
This trial will try CREPT-618, a gene therapy given by subcutaneous injection every two weeks, in adults 18–75 with locally advanced hepatocellular carcinoma who have failed standard treatments to find a safe and appropriate dose.
-
Tislelizumab before surgery for dMMR/MSI‑H stage II–III colorectal cancer
This project will try giving tislelizumab before surgery to see if it helps adults with dMMR/MSI‑H stage II–III colorectal cancer.
-
Metabolically armed tumor-infiltrating lymphocytes (Meta10-TIL) treatment for advanced solid tumors
This study will try Meta10-TIL — immune cells taken from your tumor, metabolically modified and given back — to see if it is safe and helps people with advanced solid tumors who have exhausted standard options.
-
Adaptive radiotherapy boost for prostate and bladder cancer
This trial tests whether an adaptive radiation boost delivered with a 1.5‑Tesla MR‑Linac helps people with post‑prostatectomy prostate cancer relapse and those receiving bladder‑conserving treatment.
-
Allogeneic anti-PSMA CAR‑NK cell therapy for metastatic castration‑resistant prostate cancer
This trial will try an off‑the‑shelf CAR‑NK cell therapy that targets PSMA in men with metastatic castration‑resistant prostate cancer to see if it is safe and can shrink disease.
-
GC511B CAR-T therapy for DLL3-positive relapsed or refractory small cell lung cancer
This trial will test GC511B CAR-T cells in adults whose small cell lung cancer has come back or not responded and shows DLL3, to see if the treatment is safe and can shrink tumors.
-
Neoadjuvant TACE plus atezolizumab and bevacizumab for resectable high-risk liver cancer
This study will try combining TACE with atezolizumab and bevacizumab before surgery to see if it shrinks tumors and reduces the chance of recurrence for people with resectable hepatocellular carcinoma who are at high risk of coming back.
-
Iparomlimab/Tuvonralimab with concurrent chemoradiation for locally advanced cervical cancer
This trial will test whether adding QL1706 (iparomlimab/tuvonralimab), a combined anti‑PD‑1/anti‑CTLA‑4 antibody pair, to standard concurrent cisplatin chemoradiation is safe and helpful for people with HPV‑related locally advanced cervical cancer.
-
Trastuzumab Rezetecan for HER2‑low metastatic breast cancer with visceral crisis
This Phase 2 trial tests Trastuzumab Rezetecan given every three weeks to see if it is safe and tolerable for adults with HER2‑low unresectable or metastatic breast cancer who are in visceral crisis.
-
Low-dose cytarabine combined with thalidomide for adults with newly diagnosed LCH
This trial tests whether combining low-dose cytarabine with thalidomide is safe and effective for adults newly diagnosed with multisystem or multifocal Langerhans cell histiocytosis.
-
Lenalidomide plus dexamethasone for Rosai‑Dorfman disease
This trial will try lenalidomide combined with dexamethasone to treat adults with Rosai‑Dorfman disease.
-
Smart Symptom Management Program after Esophageal Cancer Surgery
A program using a WeChat mini program to help people recover after esophageal cancer surgery is being tested to see if it improves postoperative symptoms.
-
Post-surgery radiotherapy plus sintilimab versus TACE for liver cancer with narrow surgical margins
This trial will try to see if adding radiotherapy and the immunotherapy drug sintilimab after curative liver cancer surgery prevents recurrence better than TACE in patients with narrow surgical margins and other high-risk features.
-
Neoadjuvant immunotherapy before surgery for non-small cell lung cancer
This project will see if giving immunotherapy before surgery helps adults with non‑small cell lung cancer and whether pneumonectomy, lobectomy, or non‑surgical treatments lead to better long‑term outcomes.
-
MiniPDX-guided postoperative adjuvant therapy for biliary tract cancer
This will test whether using a MiniPDX drug-sensitivity test on a patient’s tumor can guide post-surgery chemotherapy for people with biliary tract cancer.
-
Allogeneic anti-PSMA CAR-NK cell therapy for metastatic castration-resistant prostate cancer
This trial tests an off-the-shelf CAR-NK cell therapy that targets PSMA to see if it is safe and helps men with metastatic castration-resistant prostate cancer.
-
Adjuvant tislelizumab after surgery for high-risk stage I non-small cell lung cancer
This trial tests whether giving the immunotherapy drug tislelizumab for up to one year after complete surgery helps people with high-risk stage I non-small cell lung cancer whose tumors express PD-L1.
-
T-DXd with brain radiotherapy for HER2-positive and HER2-low breast cancer brain metastases
This trial tests whether giving T‑DXd (trastuzumab deruxtecan) at the same time as local brain radiotherapy is safe and helps people with HER2‑positive or HER2‑low breast cancer that has spread to the brain.
-
Golidocitinib plus PD-1 inhibitor maintenance for previously untreated extensive-stage small cell lung cancer
This trial will see if adding golidocitinib to PD-1 inhibitor maintenance helps people with previously untreated extensive-stage small cell lung cancer.
-
Umbilical cord blood-derived megakaryocyte injection for chemotherapy-related low platelets
This single-dose treatment will try to raise platelet counts in adults with cancer who developed low platelets from anti-cancer therapy.
-
Hypofractionated radiotherapy after prosthetic breast reconstruction
This study tests whether a shorter, higher-dose radiotherapy course (HFRT) works as safely and effectively as the standard longer course (CFRT) for patients who had a mastectomy with implant reconstruction.
-
Postoperative concurrent chemoradiotherapy with simultaneous integrated boost for intrahepatic cholangiocarcinoma
This treatment tests whether adding postoperative concurrent chemoradiotherapy with a simultaneous integrated boost plus oral capecitabine can reduce recurrence in adults after liver surgery for intrahepatic cholangiocarcinoma with narrow margins or positive lymph nodes.
-
Combining blood and tumor sequencing to predict response and recurrence in non-small cell lung cancer
This study will test whether combining different sequencing tests on blood and tumor tissue can detect minimal residual disease and help predict treatment response and recurrence for people with stage II–IV non‑small cell lung cancer.
-
Romiplostim N01 for chemotherapy-related low platelets in children and young adults
Romiplostim N01 will be tried to raise platelet counts in children and young adults (ages 6–24) who develop low platelets after chemotherapy for solid tumors or blood cancers.
-
Optimizing immunotherapy with pre-surgery chemotherapy and radiation for locally advanced rectal cancer
This trial will test whether adding the immunotherapy drug sintilimab to different timings and types of pre-surgery chemotherapy and radiotherapy helps people with locally advanced rectal cancer shrink tumors and preserve rectal function.
-
MRD-guided postoperative treatment for locally advanced gastric cancer
This trial will test whether using MRD results from peritoneal lavage fluid to decide on adding intraperitoneal chemotherapy after surgery can lower peritoneal relapse in people with locally advanced gastric cancer.
-
Neoadjuvant fuzuloparib plus apatinib for HRD-positive advanced ovarian cancer
This trial tests whether taking fuzuloparib together with apatinib before surgery helps people with HRD-positive advanced ovarian cancer shrink tumors and become eligible for successful surgery.
-
Computer-aided tool to predict outcomes after simultaneous colorectal and liver surgery
This project will test a web-based computer tool that helps doctors predict 1-, 3-, and 5-year recurrence and survival for adults with colorectal cancer who had liver metastases removed at the same time as their primary tumor.
-
Multi-omics blood and tissue testing to predict and monitor treatment response in small cell lung cancer
This project will test whether combining multiple molecular tests on blood and tumor tissue can predict and track treatment response in people with newly diagnosed small cell lung cancer.
-
Adding targeted radiation to remaining lung tumors after chemo‑immunotherapy
This will see if adding focused radiation to remaining tumors helps people with advanced non‑small cell lung cancer who have up to five residual lesions after first‑line chemo‑immunotherapy.
-
How local breast cancer treatments affect side effects and quality of life in Chinese patients
This project will test how surgery and related treatments (chemotherapy, radiation, hormone or targeted therapy) affect side effects and daily quality of life for people with early-stage breast cancer in China.
-
Real-world look at SKB264 in HER2-negative breast cancer that has come back or spread
This real-world study tests sacituzumab tirumotecan (SKB264) alone or with others in adults with recurrent or metastatic HER2-negative breast cancer.
-
Zanubrutinib with G-CVP for untreated Follicular Lymphoma
This study is testing if a new combination of zanubrutinib, obinutuzumab, and chemotherapy can help people with untreated follicular lymphoma feel better and stay healthy.
-
Evaluating an intelligent management system for medication adherence in breast cancer treatment
This study is testing a new patient management system to see if it helps women with HER2-positive breast cancer stick to their medication better than usual methods while they receive pyrotinib treatment.
-
Inhaled mRNA vaccine for advanced lung cancer and lung metastasis
This study is testing a new inhaled vaccine for people with advanced lung cancer to see if it can help them feel better and work well with other treatments.
-
Telpegfilgrastim versus filgrastim to prevent low white blood counts after chemotherapy in children and young adults
This study tries to see if a single long‑acting injection of telpegfilgrastim can reduce febrile neutropenia compared with daily filgrastim in 6–24‑year‑olds receiving high‑intensity chemotherapy for solid tumors.
-
Adebrelimab with chemotherapy with or without radiotherapy as neoadjuvant treatment for HER2-negative locally advanced breast cancer
This study tests whether adding Adebrelimab to standard chemotherapy, with or without radiotherapy, can improve outcomes for women with HER2-negative locally advanced breast cancer before surgery.
-
Urine protein markers to predict and monitor response to pre-surgery therapy in colorectal cancer.
This project will test whether urine proteins can predict and track how people with locally advanced colorectal cancer respond to neoadjuvant (pre-surgery) therapy.
-
Perioperative iparomlimab and tuvonralimab with or without chemotherapy for resectable NSCLC
This study will test whether giving the immunotherapy regimen QL1706 (iparomlimab and tuvonralimab) before and around the time of surgery, with or without platinum-based chemotherapy, helps people with resectable stage II–IIIB non-small cell lung cancer.
-
Combining ivonescimab with chemotherapy for treating colorectal cancer liver metastases
This study is testing if adding ivonescimab to chemotherapy can help people with colorectal cancer that has spread to the liver feel better and improve their treatment results.
-
PD-L1 antibody with VEX chemo and radiotherapy for brain metastases in HER2-negative breast cancer
This phase 2 trial tests whether adding a PD-L1 antibody to VEX metronomic chemo plus either concurrent or delayed radiotherapy helps people with advanced HER2-negative breast cancer and brain metastases.
-
Brain-metastasis breast cancer: testing a radiosensitizer with radiotherapy
This study tests whether adding a novel anti-tumor drug to brain radiotherapy helps patients with advanced breast cancer that has spread to the brain.
-
Combination treatment for advanced gastric and gastro-esophageal junction cancer
This study is testing a new combination treatment for people with advanced stomach cancer to see if it helps them before and after surgery.
-
Using cadonilimab with bevacizumab and docetaxel for advanced non-small cell lung cancer
This study is testing a new combination of treatments, including cadonilimab, bevacizumab, and docetaxel, to see if it can help people with advanced non-small cell lung cancer who haven't had success with other therapies.
-
Combination treatment for advanced pancreatic cancer
This study is testing a new combination of medications for people with advanced pancreatic cancer to see if it helps them live longer and feel better.
-
Assessing the effects of immunotherapy combined with radiotherapy in advanced breast cancer
This study is testing if combining immunotherapy with radiotherapy can help people with advanced breast cancer feel better and improve their treatment results.
-
Combination treatment for advanced triple-negative breast cancer
This study is testing a new combination of treatments for people with advanced triple-negative breast cancer to see if it helps them feel better and works safely.
-
Combining Sintilimab with Chemotherapy for Stage III Gastric Cancer Treatment
This study is testing if combining a new drug called Sintilimab with chemotherapy can help people with stage III gastric cancer feel better after their surgery.
-
Liposomal mitoxantrone combined with capecitabine and anlotinib for relapsed and refractory solid tumors in children, adolescents, and young adults
This treatment tests whether a liposomal mitoxantrone combination (with capecitabine and anlotinib) can shrink relapsed or refractory solid tumors in children, adolescents, and young adults.
-
Postoperative radiation therapy for intermediate-risk breast cancer
This study is testing if a specific type of radiation therapy after surgery can help people with intermediate-risk breast cancer have better outcomes.
-
New treatment for advanced gastric cancer using TAS-102, bevacizumab, and camrelizumab
This study is testing a new combination of medications for people with advanced stomach cancer who haven't had success with other treatments to see if it can help them.
-
Evaluating breast cancer treatment effectiveness using artificial intelligence
This study is testing whether an artificial intelligence tool can help doctors better predict how well neoadjuvant therapy works for breast cancer patients using MRI images and clinical data.
-
Comparing right and left thoracic surgical methods for treating a specific type of esophageal cancer
This study is testing whether surgery on the right or left side of the chest works better for people with a specific type of esophageal cancer after they've had chemotherapy.
-
Partial breast irradiation for early-stage breast cancer
This study is testing if a shorter 2-week radiation treatment for early-stage breast cancer is just as safe and effective as the standard 3-week treatment for women who have had breast-conserving surgery.
-
Immunotherapy rechallenge for patients with advanced solid tumors
This study is testing a new way to treat patients with advanced solid tumors who haven't responded to previous treatments by combining different immunotherapy drugs to see if it helps them.
-
FCN-159 for NF2-associated nerve sheath tumors (Phase II)
This trial tests whether the MEK inhibitor FCN-159 can shrink or control nerve sheath tumors in people aged 16 and older with NF2.
-
Combination therapy for advanced malignant peritoneal mesothelioma
This study is testing a new combination of four medications to see if it can help people with advanced malignant peritoneal mesothelioma live longer and feel better.
-
ES014 treatment for adults with advanced solid tumors
This will test whether ES014 can shrink or control advanced, unresectable solid tumors in adults who have progressed after standard therapies.
-
Nutritional therapy for esophageal cancer patients during surgery
This study tests if personalized nutritional support during surgery can help malnourished patients with esophageal cancer recover better and avoid complications.
-
Nimotuzumab with toripalimab plus gemcitabine/cisplatin for first-line recurrent or metastatic nasopharyngeal carcinoma
This trial tests whether adding nimotuzumab to toripalimab with gemcitabine and cisplatin helps people with first-line recurrent or metastatic nasopharyngeal carcinoma.
-
Evaluating outcomes of surgery in early-stage lung cancer patients
This study is testing how well different types of surgery work for people with early-stage lung cancer to help improve treatment decisions.
-
Comparing two radiation therapies for brain metastases in small-cell lung cancer
This study is testing whether two types of targeted radiation therapy can be better options than standard whole brain radiation for people with small-cell lung cancer that has spread to the brain.
-
Treatment for patients with unresectable esophageal cancer
This study is testing if a new combination of a medication called Tislelizumab with chemotherapy and radiation can help people with advanced esophageal cancer that can't be surgically removed live longer and feel better.
-
Nimotuzumab with Chemoradiotherapy for Esophageal Cancer
This study is testing if a combination of a new antibody treatment, chemotherapy, and radiation can help older or malnourished patients with advanced esophageal cancer feel better and improve their chances of recovery.
-
Combining immunotherapy and chemoradiotherapy for esophageal cancer treatment
This study is testing if combining a new immunotherapy drug with traditional chemoradiotherapy can help people with advanced esophageal cancer have better treatment results.
-
Combining fruquintinib and albumin-paclitaxel with or without PD-1 antibody for advanced gastric cancer treatment
This study is testing if combining fruquintinib and albumin-paclitaxel, with or without a PD-1 antibody, can help people with advanced gastric cancer who have already had other treatments.
-
Combining Camrelizumab and Fluzoparib for TP-53 Mutated Endometrial Cancer
This study is testing if combining two treatments, camrelizumab and fluzoparib, can help people with TP-53 mutated endometrial cancer that has come back or spread.
-
Nimotuzumab with Chemoradiotherapy for Unresectable Esophageal Cancer
This study is testing if adding a new drug called nimotuzumab to chemotherapy and radiation can help patients with advanced esophageal cancer who haven't improved with earlier treatments.
-
Combination treatment for advanced pancreatic cancer
This study is testing a new combination of treatments for people with advanced pancreatic cancer who haven't had treatment before to see if it helps manage their disease better.
-
Using a combination of drugs to treat locally advanced colorectal cancer
This study is testing if a new combination of drugs can shrink locally advanced colorectal cancer tumors enough to make them operable for surgery.
-
Testing BT02 for advanced solid tumors
This study is testing a new drug called BT02 to see if it can help adults with advanced solid tumors feel better and how safe it is.
-
Moderate-dose radiotherapy combined with Pembrolizumab for liver cancer with blood vessel blockage
This study is testing if combining a specific type of radiation therapy with the immunotherapy drug Pembrolizumab can help people with liver cancer that has blocked blood vessels feel better and live longer.
-
Combination therapy for advanced gastric cancer
This study is testing a new combination of treatments for people with advanced gastric cancer to see if it can help them respond better before surgery.
-
Outcomes of colorectal cancer treated with natural orifice surgery
This study looks at how well a new, less invasive surgery called natural orifice specimen extraction works for people with colorectal cancer, by checking their recovery and outcomes after the procedure.
-
Effects of immunonutrition on patients with advanced cervical cancer
This study is testing if a special nutrition therapy can help people with advanced cervical cancer feel better and handle their treatment side effects while they are receiving chemotherapy and radiation.
-
Evaluating a new treatment for advanced solid tumors
This study is testing a new virus injection to see if it can help people with advanced solid tumors that haven't improved with standard treatments.
-
Adaptive radiation therapy for head and neck cancer after immunotherapy
This study is testing a personalized radiation therapy plan for patients with advanced head and neck cancer who have already had immunotherapy and chemotherapy, to see if it can reduce side effects while still being effective.
-
Immunotherapy with radiotherapy and nutrition support for advanced esophageal cancer in patients who can’t tolerate standard chemoradiation
This trial tests whether adding a PD-1 inhibitor (sintilimab) to radiotherapy plus specialized nutrition helps patients with locally advanced esophageal squamous cell carcinoma who can’t tolerate standard chemoradiation.
-
Evaluating outcomes of neoadjuvant immunotherapy in lung cancer patients
This study is testing how well different immune therapies work before surgery for people with non-small cell lung cancer to see who benefits the most.
-
Guided surgery for medullary thyroid cancer using advanced imaging
This study is testing a new imaging technique to see if it can help doctors perform better surgeries for patients with medullary thyroid cancer.
-
Observational study on characteristics and outcomes of patients with surgically removed lung cancers
This study looks at patients in China who have had lung cancer surgery to see how their treatment and outcomes vary and what factors might affect their survival.
-
Adjuvant radiotherapy after liver surgery for liver cancer
This study is testing a new type of targeted radiation therapy after liver surgery to see if it helps people with liver cancer live longer and stay cancer-free.
-
Assessing safety of combining radiotherapy with new systemic therapies for breast cancer
This study is testing if it's safe to give new breast cancer treatments together with radiation therapy to see if they can work well together for patients who need both.
-
Combining chemotherapy and immunotherapy for high-risk head and neck cancer patients after surgery
This study is testing if adding a new immune treatment to standard chemotherapy after surgery can help high-risk head and neck cancer patients stay cancer-free longer.
-
Camrelizumab with chemotherapy and radiotherapy for esophageal gastric junction cancer
This study is testing if adding a new drug called camrelizumab to chemotherapy and radiotherapy can help people with esophageal gastric junction cancer have better surgery results and live longer.
-
Comparing Cadonilimab with FOLFOX to FOLFOX alone for advanced colorectal cancer treatment
This study is testing whether adding a new drug called Cadonilimab to the FOLFOX chemotherapy can help people with advanced colorectal cancer do better than just using FOLFOX alone.
-
Personalized cell therapy for advanced solid tumors
This study is testing a personalized cell therapy to see if it can help people with tough-to-treat advanced solid tumors feel better.
-
Safety of omitting dissection of specific lymph nodes in rectal cancer surgery
This study is testing if skipping the removal of a specific lymph node during rectal cancer surgery is safe and if it can still help patients live just as long.
-
Thyroxine therapy after thyroid surgery for low-risk cancer
This study tests if taking thyroxine after surgery for low-risk thyroid cancer can help keep patients healthy and prevent the cancer from coming back.
-
Combining PD-1 inhibitors with chemotherapy and radiotherapy for metastatic esophageal cancer
This study is testing if adding PD-1 inhibitors to chemotherapy and radiotherapy can help people with advanced esophageal cancer live longer and feel better.
-
Radiotherapy for patients with metastatic esophageal cancer responding to immunotherapy and chemotherapy
This study is testing if adding radiation treatment can help people with advanced esophageal cancer who are responding well to immunotherapy and chemotherapy live longer and better manage their disease.
-
Prophylactic central neck dissection for low-risk papillary thyroid cancer
This study is testing if a specific type of surgery can help people with low-risk thyroid cancer live longer and have fewer recurrences of the disease.
-
Using NV-001 vaccine to treat advanced solid tumors
This study is testing a new vaccine made from patients' own tumor tissues to see if it can safely help people with advanced solid tumors who haven't had success with other treatments.
-
Combining Surufatinib with Temozolomide and S-1 for treating advanced neuroendocrine tumors
This study is testing a new combination of three medications to see if it can help people with advanced neuroendocrine tumors who haven't had treatment before.
-
Combining chidamide and everolimus for advanced breast cancer treatment
This study is testing whether combining a new drug called chidamide with hormone therapy helps people with a specific type of advanced breast cancer, while also seeing if everolimus works better for those with a different gene mutation.
-
LK101 combined with PD-1 or PD-L1 therapy for lung cancer treatment
This study is testing a new vaccine combined with existing lung cancer treatments to see if it can help patients with advanced lung cancer who haven't responded to other therapies.
-
Postoperative treatment for head and neck cancer based on response to chemotherapy and immunotherapy
This study is testing different follow-up treatments for patients with advanced head and neck cancer after they have received chemotherapy and immunotherapy to see which approach helps them stay cancer-free and live longer.
-
Radiotherapy options for low-risk breast cancer patients
This study is testing a new type of radiation treatment for low-risk breast cancer patients to see if it can be safely given after surgery.
-
Using 18F-PSMA PET/CT imaging for detecting prostate-specific tumors
This study is testing a new type of imaging to see if it can better find prostate-specific tumors in patients with prostate cancer and other related cancers.
-
Using Al18F-octreotide PET/CT for Neuroendocrine Tumors
This study is testing a new type of imaging called Al18F-octreotide PET/CT to see if it can help doctors better diagnose neuroendocrine tumors in patients who may have them.
-
Preoperative tumor-bed boost followed by oncoplastic surgery for early stage breast cancer
This study is testing if giving a special dose of radiation to the tumor area before surgery can help younger patients with early stage breast cancer have better surgery results and fewer side effects.
-
Optimizing post-surgery treatments for early-stage breast cancer using MRD strategy
This study is testing if using a new strategy based on minimal residual disease can help improve post-surgery treatment for early-stage breast cancer patients by giving more intensive therapy to those at higher risk.
-
Comparing surgery and chemoradiotherapy for cervical esophageal cancer
This study is testing whether surgery or a combination of chemotherapy and radiation works better for people with cervical esophageal cancer.
-
Pre-surgery ultra-hypofractionated radiation for retroperitoneal soft tissue sarcoma
This study tests a very short course of pre-surgery high-dose radiation followed by surgery to see if it is safe and manageable for people with retroperitoneal soft tissue sarcoma.
-
Combining Sintilimab, Anlotinib, and Chemotherapy for Advanced Pleural Mesothelioma
This study is testing a new combination of Sintilimab, Anlotinib, and chemotherapy to see if it helps people with advanced pleural mesothelioma who haven't had treatment before.
-
MR‑guided short-course high-dose radiation for prostate cancer (SMART‑P01 & P02)
This trial tests MR‑guided, very short-course high‑dose radiation for men with localized or limited metastatic prostate cancer to see if it is tolerable and effective.
-
Preoperative intensity-modulated radiotherapy with concurrent anlotinib for localized extremity and trunk soft tissue sarcoma
This test combines preoperative IMRT and the drug anlotinib to see if it improves outcomes for adults with primary soft tissue sarcoma of the arms, legs, or trunk.
-
Pembrolizumab with chemotherapy for advanced head and neck cancer in China
This study is testing if combining pembrolizumab with chemotherapy can help people in China with advanced head and neck cancer feel better and live longer.
-
Monitoring the safety of Sintilimab in Chinese patients
This study is testing how safe Sintilimab is for Chinese patients by closely watching for any side effects while they receive the treatment.
-
Neoadjuvant treatments for esophageal cancer
This study is testing different combinations of treatments for people with esophageal cancer to see if they can improve outcomes compared to just having surgery.
-
Chemoradiotherapy for esophageal and esophagogastric junction cancer
This study is testing a new combination of chemotherapy, radiation, and immune therapies to see if it helps people with advanced esophageal or esophagogastric junction cancer live longer and feel better.
-
Precision medicine approach for treating rare tumors
This study is testing new targeted therapies and immunotherapy for people with advanced rare tumors that haven't improved with standard treatments, to see if these options work better based on their specific genetic changes.
-
Chemoradiotherapy for patients with unresectable esophageal cancer
This study is testing a new combination of chemotherapy and radiation to see if it helps people with advanced esophageal cancer while also focusing on their nutrition to improve their treatment experience.
-
Using Huaier granules to prevent colorectal cancer recurrence after surgery
This study is testing if Huaier granules can help prevent colorectal cancer from coming back after surgery in patients with certain stages of the disease.
-
Using MRI and CT to Evaluate Tumor Response in Esophageal Cancer Treatment
This study tests whether MRI can better track how well treatment is working for people with esophageal cancer compared to regular CT scans.
Quick answers
How many clinical trials run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences are recruiting right now?
149, as of November 12, 2026. 4 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 64, Phase 3: 12, Phase 1: 10, Early Phase 1: 9. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.